Andere Kunden interessierten sich auch für
![The Market Return To Pharmaceutical Product Approval]( "The Market Return To Pharmaceutical Product Approval")
The Market Return To Pharmaceutical Product Approval32,99 €![HUMAN RIGHTS AND MULTINATIONAL CORPORATIONS]( "HUMAN RIGHTS AND MULTINATIONAL CORPORATIONS")
HUMAN RIGHTS AND MULTINATIONAL CORPORATIONS79,00 €![Multinational Companies and Rural Development]( "Multinational Companies and Rural Development")
Multinational Companies and Rural Development51,99 €![Leading Pharmaceutical Innovation]( "Leading Pharmaceutical Innovation")
Leading Pharmaceutical Innovation42,99 €![Human resource management in oil multinational companies in cameroon]( "Human resource management in oil multinational companies in cameroon")
Human resource management in oil multinational companies in cameroon61,99 €![Outlook on labor cost development in China (Shanghai region in particular) as a road map for multinational corporations (MNCs)]( "Outlook on labor cost development in China (Shanghai region in particular) as a road map for multinational corporations (MNCs)")
Outlook on labor cost development in China (Shanghai region in particular) as a road map for multinational corporations (MNCs)27,95 €![Pharmaceutical Marketing & Prescription Habits of Doctors]( "Pharmaceutical Marketing & Prescription Habits of Doctors")
Pharmaceutical Marketing & Prescription Habits of Doctors36,99 €
The opening-up of Chinese economy in 1978 and the
subsequent reforms provided multinational
corporations with tremendous opportunities to invest
in and explore the world's largest developing
market. China, however, presents a complicated and
difficult operating business environment for foreign
investors. This PhD thesis demonstrates a
comprehensive, multi-level study on 44 multinational
pharmaceutical firms' strategic planning and
implementation of foreign direct investment (FDI)
strategies in China during the first tweenty years
of China's open-door policy and economic reform era.
The study developed an integrated master conceptual
framework and examined a series of key issues
related to the strategic FDI decision-making and
implementation processes,
including FDI determinants, entry mode choice
between joint venture and wholly owned subsidiary,
joint venture partners selection, FDI operating
location choice within China, and the
determinants of FDI effectiveness and success in
China. The thesis received exemplary reports from
all examiners, and the PhD candidate was awarded
the Research Achievement Prize" by Swinburne
University.
subsequent reforms provided multinational
corporations with tremendous opportunities to invest
in and explore the world's largest developing
market. China, however, presents a complicated and
difficult operating business environment for foreign
investors. This PhD thesis demonstrates a
comprehensive, multi-level study on 44 multinational
pharmaceutical firms' strategic planning and
implementation of foreign direct investment (FDI)
strategies in China during the first tweenty years
of China's open-door policy and economic reform era.
The study developed an integrated master conceptual
framework and examined a series of key issues
related to the strategic FDI decision-making and
implementation processes,
including FDI determinants, entry mode choice
between joint venture and wholly owned subsidiary,
joint venture partners selection, FDI operating
location choice within China, and the
determinants of FDI effectiveness and success in
China. The thesis received exemplary reports from
all examiners, and the PhD candidate was awarded
the Research Achievement Prize" by Swinburne
University.